S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
INBP · Integrated BioPharma, Inc.
OTC MARKETS - Real Time Price • USD
$0.18
-0.00
(-1.32%)
● Overnight
DAY'S RANGE
$0.18
$0.17
$0.18
52-WEEK RANGE
$0.18
$0.14
$0.42
What's happening
- INBP is down 1.32% today, trading at $0.18. — Live quote
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
INBP
-49.30%
vs S&P 500
-66.80%
1-YEAR RETURN
INBP
-41.25%
vs S&P 500
-48.11%
6-MONTH RETURN
INBP
-49.48%
3-MONTH RETURN
INBP
-7.69%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2025-07-26 (Q2 2025)
$0.00
Est. $—
Valuation Measures & Ratios
Enterprise Value4$1.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.13
Price / Book70.32
EV4 / Revenue0.03
EV4 / EBITDA1.40
Profit Margin-6.48%
Operating Margin-6.17%
Return on Equity (ROE8)-14.78%
Return on Assets (ROA9)-11.24%
Avg Volume (3M)12,170
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4
Change from Prior Settlement+0.00%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-25; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -30.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -6.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -41.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on INBP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Mar '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | -$276.0K | $29.0K | $1.0M | $1.6M | $1.2M | $1.4M | $1.2M | $520.0K |
| Operating income | -$1.1M | -$914.0K | $163.0K | $739.0K | $202.0K | $490.0K | $355.0K | -$452.0K |
| Net income | -$837.0K | -$762.0K | $123.0K | $611.0K | $116.0K | $259.0K | $285.0K | -$382.0K |
| EPS (diluted) | $-0.03 | $-0.03 | $0.00 | $0.02 | $0.01 | $0.01 | $0.01 | $-0.01 |
| EPS (basic) | $-0.03 | $-0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $-0.01 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $25.3M | $26.7M | $23.5M | $25.5M | $24.9M | $25.7M | $25.7M | $26.2M |
| Total liabilities | $7.7M | $7.7M | $3.8M | $5.1M | $4.6M | $5.3M | $5.9M | $6.6M |
| Stockholders' equity | $17.7M | $19.0M | $19.8M | $20.5M | $20.3M | $20.4M | $19.7K | $18.6M |
| Total current assets | $17.4M | $18.0M | $17.8M | $19.6M | $18.8M | $18.5M | $18.2M | $18.3M |
| Total current liabilities | $5.8M | $5.5M | $3.5M | $4.8M | $4.2M | $5.0M | $5.6M | $6.0M |
| Cash & equivalents | $4.5M | $5.8M | $5.3M | $4.7M | $3.6M | $3.0M | $2.5M | $2.3M |
| Accounts receivable | $3.3M | $3.7M | $3.6M | $4.0M | $5.4M | $5.1M | $4.2M | $4.4M |
| Inventory | $9.1M | $8.1M | $8.4M | $10.5M | $9.4M | $10.1M | $11.1M | $11.2M |
| Other current assets | $432.0K | $374.0K | $550.0K | $440.0K | $356.0K | $428.0K | $398.0K | $432.0K |
| Property, plant & equipment | $1.8M | $1.7M | $1.8M | $1.8M | $1.7M | $1.8M | $1.8M | $1.9M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.2M | $3.0M | $2.1M | $2.8M | $2.3M | $2.5M | $2.8M | $2.8M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $62.0K | $62.0K | $61.0K | $62.0K | $62.0K | $61.0K | $61.0K | $60.0K |
| Retained earnings | -$34.3M | -$32.9M | -$32.1M | -$31.3M | -$31.4M | -$31.2M | -$31.9M | -$32.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.2M | $517.0K | $617.0K | $1.3M | $591.0K | $616.0K | $201.0K | $657.0K |
| Investing cash flow | -$149.0K | $6.0K | -$24.0K | -$173.0K | -$4.0K | -$116.0K | -$29.0K | -$56.0K |
| Financing cash flow | -$12.0K | -$11.0K | -$11.0K | -$11.0K | $67.0K | $0 | $18.0K | -$7.0K |
| Free cash flow | -$1.3M | $517.0K | $593.0K | $1.1M | $601.0K | $500.0K | $172.0K | $601.0K |
| Capital expenditures | $149.0K | $0 | $24.0K | $173.0K | -$10.0K | $116.0K | $29.0K | $56.0K |
| Depreciation & amortization | $70.0K | $68.0K | $78.0K | $77.0K | $71.0K | $79.0K | $83.0K | $85.0K |
| Share-based compensation | $51.0K | $50.0K | $42.0K | $49.0K | $44.0K | $45.0K | $43.0K | $53.0K |
| Deferred income taxes | $512.0K | -$203.0K | -$119.0K | $68.0K | $772.0K | $244.0K | $51.0K | $197.0K |
| Change in accounts receivable | -$321.0K | $63.0K | -$391.0K | -$1.4M | $369.0K | $852.0K | -$157.0K | -$283.0K |
| Change in inventory | $1.0M | -$244.0K | -$2.1M | $1.1M | -$715.0K | -$989.0K | -$158.0K | -$20.0K |
| Change in accounts payable | $227.0K | $821.0K | -$656.0K | $533.0K | -$238.0K | -$271.0K | $45.0K | $253.0K |
Income statement
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | $800.0K | $5.6M | $3.9M | $4.1M | $6.6M |
| Operating income | -$2.7M | $2.0M | $251.0K | $120.0K | $2.7M |
| Net income | -$2.8M | $808.0K | $112.0K | -$34.0K | $3.8M |
| EPS (diluted) | $-0.09 | $0.03 | $0.00 | $0.00 | $0.12 |
| EPS (basic) | $-0.09 | $0.03 | $0.00 | $0.00 | $0.13 |
Balance sheet
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Total assets | $25.3M | $24.9M | $26.2M | $25.4M | $25.2M |
| Total liabilities | $7.7M | $4.6M | $7.0M | $6.6M | $6.7M |
| Stockholders' equity | $17.7M | $20.3M | $19.2M | $18.9M | $18.6M |
| Total current assets | $17.4M | $18.8M | $17.9M | $16.4M | $16.6M |
| Total current liabilities | $5.8M | $4.2M | $6.1M | $4.8M | $5.3M |
| Cash & equivalents | $4.5M | $3.6M | $1.7M | $1.3M | $331.0K |
| Accounts receivable | $3.3M | $5.4M | $4.7M | $4.5M | $4.9M |
| Inventory | $9.1M | $9.4M | $11.2M | $10.3M | $11.1M |
| Other current assets | $432.0K | $356.0K | $286.0K | $284.0K | $352.0K |
| Property, plant & equipment | $1.8M | $1.7M | $1.8M | $1.7M | $1.9M |
| Intangible assets | — | — | — | — | — |
| Accounts payable | $3.2M | $2.3M | $2.5M | $2.3M | $3.2M |
| Short-term debt | — | — | — | $42.0K | $32.0K |
| Long-term debt | — | — | — | $7.0K | $53.0K |
| Common stock & paid-in capital | $62.0K | $62.0K | $60.0K | $60.0K | $60.0K |
| Retained earnings | -$34.3M | -$31.4M | -$32.2M | -$32.3M | -$32.3M |
Cash flow
| Line item | Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 |
|---|---|---|---|---|---|
| Operating cash flow | $1.2M | $2.1M | $943.0K | $1.2M | $4.1M |
| Investing cash flow | -$340.0K | -$205.0K | -$553.0K | -$111.0K | -$465.0K |
| Financing cash flow | -$45.0K | $78.0K | -$29.0K | -$136.0K | -$3.5M |
| Free cash flow | $895.0K | $1.9M | $390.0K | $1.1M | $3.6M |
| Capital expenditures | $346.0K | $191.0K | $553.0K | $116.0K | $486.0K |
| Depreciation & amortization | $293.0K | $318.0K | $307.0K | $351.0K | $336.0K |
| Share-based compensation | $192.0K | $185.0K | $252.0K | $320.0K | $369.0K |
| Deferred income taxes | $258.0K | $1.3M | $125.0K | $72.0K | -$1.5M |
| Change in accounts receivable | -$2.1M | $781.0K | $120.0K | -$374.0K | -$875.0K |
| Change in inventory | -$220.0K | -$1.9M | $983.0K | -$794.0K | -$640.0K |
| Change in accounts payable | $925.0K | -$211.0K | $244.0K | -$921.0K | -$218.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding INBP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-21 to 2026-04-15
Recent transactions
- Most recent: Milmoe William H. (Director) — Gift of 8,966,547 shares on 2026-04-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Milmoe William H. | Director | Gift | 2026-04-15 | 8,966,547 |
| DESANTIS CARL | 10% owner | Gift | 2026-04-15 | 8,966,547 |
| DeSantis Damon | Director | Gift | 2026-04-15 | 8,966,547 |
| RIVA SHEPPARD | Co-Chief Executive Officer | Grant / award | 2025-05-21 | 144,445 |
| KAY CHRISTINA | Co-Chief Executive Officer | Grant / award | 2025-05-21 | 144,445 |
| Masi Dina | Chief Financial Officer | Grant / award | 2025-05-21 | 135,000 |
| Canarick Robert | Director | Grant / award | 2025-05-21 | 175,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-15 | Milmoe William H. | Director | Gift | 8,966,547 | $0.00 |
| 2026-04-15 | Milmoe William H. | Director | Gift | 2,235,417 | $0.00 |
| 2026-04-15 | DESANTIS CARL | 10% owner | Gift | 8,966,547 | $0.00 |
| 2026-04-15 | DESANTIS CARL | 10% owner | Gift | 2,235,417 | $0.00 |
| 2026-04-15 | DeSantis Damon | Director | Gift | 8,966,547 | $0.00 |
| 2026-04-15 | DeSantis Damon | Director | Gift | 2,235,417 | $0.00 |
| 2026-03-24 | DESANTIS CARL | 10% owner | Gift | 1,356,293 | $0.00 |
| 2026-03-24 | DESANTIS CARL | 10% owner | Gift | 7,392 | $0.00 |
| 2026-03-24 | Milmoe William H. | Director | Gift | 1,356,293 | $0.00 |
| 2026-03-24 | Milmoe William H. | Director | Gift | 7,392 | $0.00 |
| 2026-03-24 | DeSantis Damon | Director | Gift | 1,356,293 | $0.00 |
| 2026-03-24 | DeSantis Damon | Director | Gift | 7,392 | $0.00 |
| 2025-05-30 | Milmoe William H. | Director | Grant / award | 50,000 | $0.09 |
| 2025-05-21 | RIVA SHEPPARD | Co-Chief Executive Officer | Grant / award | 144,445 | $0.09 |
| 2025-05-21 | KAY CHRISTINA | Co-Chief Executive Officer | Grant / award | 144,445 | $0.09 |
| 2025-05-21 | Masi Dina | Chief Financial Officer | Grant / award | 135,000 | $0.09 |
| 2025-05-21 | Canarick Robert | Director | Grant / award | 175,000 | $0.09 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-25 | 8-K | 2026-09-25 | View on SEC.gov → |
| 2026-09-25 | 10-K | 2026-06-30 | View on SEC.gov → |
| 2026-08-20 | 8-K | 2026-08-20 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-05-08 | 8-K | 2026-05-08 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-17 | 4 | 2026-03-24 | View on SEC.gov → |
| 2026-04-17 | 4 | 2026-04-15 | View on SEC.gov → |
Recent news
Headlines about INBP (Integrated BioPharma, Inc.). Links open the publisher — we don’t host full articles.
-
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
Yahoo Finance · 2026-09-25 -
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Yahoo Finance · 2026-05-08 -
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
Yahoo Finance · 2026-02-11 -
Integrated BioPharma GAAP EPS of $0.00, revenue of $12.69M
Seeking Alpha · 2025-11-11 -
Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
Yahoo Finance · 2025-11-10
No headlines in this category right now — try “All”.